Page last updated: 2024-11-04

vorinostat and Hemorrhagic Thrombocythemia

vorinostat has been researched along with Hemorrhagic Thrombocythemia in 4 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
" We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients."9.19Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. ( Ahlstrand, E; Andersen, CL; Andreasson, B; Bareford, D; Bjerrum, OW; Bjørn, ME; Ejerblad, E; Fernandes, S; Grønbæk, K; Harrison, C; Hasselbalch, HC; Jensen, MK; Klausen, TW; Knapper, S; Kruse, T; Larsen, H; Linder, O; Löfvenberg, E; McMullin, MF; Mourits-Andersen, T; Samuelsson, J; Skov, V; Thomassen, M; Vestergaard, H; Zweegman, S, 2014)
" We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients."5.19Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. ( Ahlstrand, E; Andersen, CL; Andreasson, B; Bareford, D; Bjerrum, OW; Bjørn, ME; Ejerblad, E; Fernandes, S; Grønbæk, K; Harrison, C; Hasselbalch, HC; Jensen, MK; Klausen, TW; Knapper, S; Kruse, T; Larsen, H; Linder, O; Löfvenberg, E; McMullin, MF; Mourits-Andersen, T; Samuelsson, J; Skov, V; Thomassen, M; Vestergaard, H; Zweegman, S, 2014)
"Treatment with vorinostat resulted in a younger MA in PV patients and older MA in ET patients, in both cases a trend towards the normal chronological age."2.90Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. ( Andersen, C; Greenfield, G; Grinfeld, J; Hasselbalch, HC; McMullin, MF; McPherson, S; Mills, KI; Nangalia, J, 2019)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
McPherson, S1
Greenfield, G1
Andersen, C1
Grinfeld, J1
Hasselbalch, HC3
Nangalia, J1
Mills, KI1
McMullin, MF3
Andersen, CL2
Ejerblad, E2
Zweegman, S2
Harrison, C2
Fernandes, S2
Bareford, D2
Knapper, S2
Samuelsson, J2
Löfvenberg, E2
Linder, O2
Andreasson, B2
Ahlstrand, E2
Jensen, MK2
Bjerrum, OW2
Vestergaard, H2
Larsen, H2
Klausen, TW2
Mourits-Andersen, T2
Bjørn, ME1
Skov, V1
Thomassen, M1
Kruse, T1
Grønbæk, K1
Lee, J1

Trials

3 trials available for vorinostat and Hemorrhagic Thrombocythemia

ArticleYear
Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat.
    Experimental hematology, 2019, Volume: 79

    Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Epigenesis, Geneti

2019
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Fatigue; Female; Gastrointestinal Diseases; Hematologic

2013
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
    Leukemia research, 2014, Volume: 38, Issue:7

    Topics: Adipokines; Adult; Aged; Aged, 80 and over; C-Reactive Protein; Chitinase-3-Like Protein 1; Female;

2014

Other Studies

1 other study available for vorinostat and Hemorrhagic Thrombocythemia

ArticleYear
Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.
    Annals of hematology, 2009, Volume: 88, Issue:7

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Blood Transfusion; Humans; Hyd

2009